VALLON PHARMACEUTICALS INC (VLON) Stock Price, Quote, News and Overview
NASDAQ:VLON - Nasdaq - US92023M1018 - Common Stock - Currency: USD
VLON Quote, Performance and Key Statistics
0.4
-0.06 (-13.04%)
The current stock price of VLON is 0.4 USD. In the past month the price decreased by -2.44%. In the past year, price decreased by -82.38%.
VLON Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About VLON
Company Profile
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-10. The firm is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company’s lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company’s second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.
Company Info
VALLON PHARMACEUTICALS INC
Two Logan Square, 100 N. 18Th Street, Suite 300
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: David Baker
Employees: 2
Company Website: https://www.vallon-pharma.com/
Phone: 12676078255.0
VALLON PHARMACEUTICALS INC / VLON FAQ
What is the stock price of VALLON PHARMACEUTICALS INC today?
The current stock price of VLON is 0.4 USD. The price decreased by -13.04% in the last trading session.
What is the ticker symbol for VALLON PHARMACEUTICALS INC stock?
The exchange symbol of VALLON PHARMACEUTICALS INC is VLON and it is listed on the Nasdaq exchange.
On which exchange is VLON stock listed?
VLON stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VALLON PHARMACEUTICALS INC stock?
7 analysts have analysed VLON and the average price target is 12.24 USD. This implies a price increase of 2960% is expected in the next year compared to the current price of 0.4. Check the VALLON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VALLON PHARMACEUTICALS INC worth?
VALLON PHARMACEUTICALS INC (VLON) has a market capitalization of 5.39M USD. This makes VLON a Nano Cap stock.
How many employees does VALLON PHARMACEUTICALS INC have?
VALLON PHARMACEUTICALS INC (VLON) currently has 2 employees.
What are the support and resistance levels for VALLON PHARMACEUTICALS INC (VLON) stock?
VALLON PHARMACEUTICALS INC (VLON) has a support level at 0.38. Check the full technical report for a detailed analysis of VLON support and resistance levels.
Should I buy VALLON PHARMACEUTICALS INC (VLON) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VLON, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VLON, evaluating the profitability, health, valuation and growth aspects
- VALLON PHARMACEUTICALS INC (VLON) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VALLON PHARMACEUTICALS INC (VLON) Sales and EPS estimates to see what analysts future expectations are.
- VALLON PHARMACEUTICALS INC (VLON) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VALLON PHARMACEUTICALS INC (VLON) Insider and Institutional Ownership to learn about the owners and their transactions.
- VALLON PHARMACEUTICALS INC (VLON) Stock Chart to make your own analysis
- VALLON PHARMACEUTICALS INC (VLON) Latest news and press-releases to stay up to date.
Does VALLON PHARMACEUTICALS INC (VLON) stock pay dividends?
VLON does not pay a dividend.
When does VALLON PHARMACEUTICALS INC (VLON) report earnings?
VALLON PHARMACEUTICALS INC (VLON) will report earnings on 2023-05-08, before the market open.
What is the Price/Earnings (PE) ratio of VALLON PHARMACEUTICALS INC (VLON)?
VALLON PHARMACEUTICALS INC (VLON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
VLON Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VLON. When comparing the yearly performance of all stocks, VLON is a bad performer in the overall market: 76.9% of all stocks are doing better.
VLON Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VLON. Both the profitability and financial health of VLON have multiple concerns.
VLON Financial Highlights
Over the last trailing twelve months VLON reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 44.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
VLON Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to VLON. The Buy consensus is the average rating of analysts ratings from 7 analysts.